Abstract
Pancreatic adenocarcinoma (PAC) is a highly lethal disease for human being. Surgery in the past 100 years, novel drug combination and neoadjuvant therapy haven′t changed the prognosis of PAC fundamentally. Traditionally, authors only focused on the treatment in term of morphological changes, while it′s tumor biology that will ultimately determine the long-term survival of PAC patients. Surgeons should continuously pursue the radical resection of pancreatic cancer, however, with the guidance of tumor biology. Omics′ researches, artificial intelligence and next generation platform of translational study will improve our understanding and treatment for PAC. Key words: Pancreas; Neoplasms; Morphology; Biology
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
